AR088582A1 - Profarmaco de adrenomedulina basado en polietilenglicol y el uso del mismo - Google Patents

Profarmaco de adrenomedulina basado en polietilenglicol y el uso del mismo

Info

Publication number
AR088582A1
AR088582A1 ARP120104059A ARP120104059A AR088582A1 AR 088582 A1 AR088582 A1 AR 088582A1 AR P120104059 A ARP120104059 A AR P120104059A AR P120104059 A ARP120104059 A AR P120104059A AR 088582 A1 AR088582 A1 AR 088582A1
Authority
AR
Argentina
Prior art keywords
polyethylene glycol
profarmacy
adrenomeduline
same
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120104059A
Other languages
English (en)
Inventor
Dr Wunder Frank
Dr Kbberling Johannes
Dr Lerchen Hans
Georg-Dr Griebenow Nils
Dr Schohe-Loop Rudolf
Dr Wittrock Sven
Koellnberger Maria
Dr Redlich Gorden
Dr Marley July
Dr Pritchard Iain
Dr Flamme Ingo
Dr Knorr Andreas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Publication of AR088582A1 publication Critical patent/AR088582A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente se refiere a un profármaco de adrenomedulina basado en polietilenglicol (PEO), a procedimientos para la preparación del mismo, al uso del mismo en el tratamiento y/o la prevención de enfermedades, y al uso del mismo para producir medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente de trastornos cardiovasculares, edematosos y/o inflamatorios.
ARP120104059A 2011-11-03 2012-10-30 Profarmaco de adrenomedulina basado en polietilenglicol y el uso del mismo Pending AR088582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03

Publications (1)

Publication Number Publication Date
AR088582A1 true AR088582A1 (es) 2014-06-18

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120104059A Pending AR088582A1 (es) 2011-11-03 2012-10-30 Profarmaco de adrenomedulina basado en polietilenglicol y el uso del mismo
ARP180103212A AR113830A2 (es) 2011-11-03 2018-11-05 Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103212A AR113830A2 (es) 2011-11-03 2018-11-05 Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo

Country Status (45)

Country Link
US (3) US9603936B2 (es)
EP (2) EP2773376B1 (es)
JP (2) JP5995984B2 (es)
KR (2) KR102004668B1 (es)
CN (2) CN103998063B (es)
AR (2) AR088582A1 (es)
AU (2) AU2012331244B2 (es)
BR (1) BR112014010708B1 (es)
CA (1) CA2854134C (es)
CL (1) CL2014000948A1 (es)
CO (1) CO7020863A2 (es)
CR (1) CR20140184A (es)
CU (1) CU24184B1 (es)
CY (2) CY1117354T1 (es)
DK (2) DK2773376T3 (es)
DO (2) DOP2014000078A (es)
EA (2) EA025631B1 (es)
EC (2) ECSP14013326A (es)
ES (2) ES2568063T3 (es)
GT (1) GT201400085A (es)
HK (1) HK1246147A1 (es)
HR (2) HRP20160285T1 (es)
HU (2) HUE036535T2 (es)
IL (3) IL232037B (es)
IN (1) IN2014CN03290A (es)
JO (2) JOP20190001B1 (es)
LT (1) LT3075395T (es)
MA (1) MA35618B1 (es)
ME (1) ME02379B (es)
MX (2) MX350341B (es)
MY (2) MY173372A (es)
NO (1) NO3075395T3 (es)
PE (2) PE20181493A1 (es)
PL (2) PL2773376T3 (es)
PT (1) PT3075395T (es)
RS (2) RS56819B1 (es)
SG (2) SG11201400924TA (es)
SI (2) SI3075395T1 (es)
TN (1) TN2014000185A1 (es)
TR (1) TR201802124T4 (es)
TW (2) TWI583396B (es)
UA (1) UA111098C2 (es)
UY (2) UY37922A (es)
WO (1) WO2013064508A1 (es)
ZA (1) ZA201600434B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
JP6685046B2 (ja) * 2014-03-20 2020-04-22 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
EP3197481A1 (en) 2014-09-26 2017-08-02 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
CN114805540A (zh) * 2015-09-18 2022-07-29 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN110678550B (zh) 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン－類似体およびその使用
WO2021112220A1 (ja) * 2019-12-05 2021-06-10 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
CA3177217A1 (en) 2020-04-03 2021-10-07 Bayer Aktiengesellschaft Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
CA3177220A1 (en) * 2020-04-03 2021-10-07 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
MX2023002850A (es) 2020-09-10 2023-07-07 Precirix N V Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap).
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
CN117957021A (zh) 2021-08-20 2024-04-30 拜耳公司 用于制备聚乙二醇化肾上腺髓质素的方法、它的中间体及其用途
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
WO2005010410A2 (en) 2003-07-23 2005-02-03 Sierracin Corporation Composite seal and window assembly
BR122019000248B8 (pt) 2004-03-23 2021-07-27 Complex Biosystems Gmbh reagente de ligador de pró-fármaco de cascata polimérico
ATE534664T1 (de) 2004-05-24 2011-12-15 Inst Cardiologie Montreal Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
JP2010513476A (ja) * 2006-12-20 2010-04-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
EP2155781B1 (en) 2007-05-11 2013-03-13 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커

Also Published As

Publication number Publication date
CN103998063B (zh) 2016-09-21
WO2013064508A1 (en) 2013-05-10
NO3075395T3 (es) 2018-04-21
HUE036535T2 (hu) 2018-07-30
CO7020863A2 (es) 2014-08-11
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
KR102004668B1 (ko) 2019-07-26
MX350341B (es) 2017-09-04
CY1117354T1 (el) 2017-04-26
EA201600495A1 (ru) 2016-10-31
IL232037B (en) 2018-12-31
EP2773376A1 (en) 2014-09-10
TW201720467A (zh) 2017-06-16
JOP20190001A1 (ar) 2017-06-16
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
TW201332573A (zh) 2013-08-16
EP2773376B1 (en) 2016-01-13
TWI653051B (zh) 2019-03-11
MY194197A (en) 2022-11-21
KR101965467B1 (ko) 2019-04-03
AU2017203423A1 (en) 2017-06-08
US9603936B2 (en) 2017-03-28
US10035818B2 (en) 2018-07-31
IL252281A0 (en) 2017-08-31
DK2773376T3 (en) 2016-04-18
IL258229B (en) 2020-02-27
BR112014010708A2 (pt) 2017-04-25
MY173372A (en) 2020-01-21
PL2773376T3 (pl) 2016-07-29
DK3075395T3 (en) 2018-02-19
HRP20180319T1 (hr) 2018-03-23
JP6177975B2 (ja) 2017-08-09
DOP2014000078A (es) 2014-07-15
JOP20190001B1 (ar) 2022-03-14
HUE027333T2 (en) 2016-09-28
CU24184B1 (es) 2016-07-29
PL3075395T3 (pl) 2018-04-30
SI3075395T1 (en) 2018-03-30
TR201802124T4 (tr) 2018-03-21
LT3075395T (lt) 2018-02-26
ECSP14013326A (es) 2014-05-31
ES2659195T3 (es) 2018-03-14
SG10201607516SA (en) 2016-10-28
EA201400528A1 (ru) 2014-10-30
TWI583396B (zh) 2017-05-21
EA029410B1 (ru) 2018-03-30
US20140287984A1 (en) 2014-09-25
AU2017203423B2 (en) 2019-01-31
IL258229A (en) 2018-06-28
AR113830A2 (es) 2020-06-17
US20170204137A1 (en) 2017-07-20
PE20141219A1 (es) 2014-09-13
RS54623B1 (en) 2016-08-31
NZ714621A (en) 2017-10-27
MX2014004384A (es) 2014-04-30
ES2568063T3 (es) 2016-04-27
CN107412740A (zh) 2017-12-01
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
CN107412740B (zh) 2021-02-09
DOP2018000203A (es) 2018-10-15
CY1119897T1 (el) 2018-06-27
US9649363B2 (en) 2017-05-16
PE20181493A1 (es) 2018-09-18
CU20140051A7 (es) 2014-10-02
CN103998063A (zh) 2014-08-20
GT201400085A (es) 2015-03-05
EP3075395B1 (en) 2017-11-22
UY37922A (es) 2018-11-30
CL2014000948A1 (es) 2014-09-05
HK1246147A1 (zh) 2018-09-07
JP2017014264A (ja) 2017-01-19
EA025631B1 (ru) 2017-01-30
SI2773376T1 (sl) 2016-05-31
CR20140184A (es) 2014-05-27
RS56819B1 (sr) 2018-04-30
ZA201600434B (en) 2017-05-31
IN2014CN03290A (es) 2015-07-03
JP2014532682A (ja) 2014-12-08
UY34419A (es) 2013-05-31
PT3075395T (pt) 2018-02-13
US20160367636A1 (en) 2016-12-22
CA2854134A1 (en) 2013-05-10
BR112014010708B1 (pt) 2021-03-02
NZ622997A (en) 2015-12-24
IL232037A0 (en) 2014-05-28
ECSP18071104A (es) 2018-10-31
JO3385B1 (ar) 2019-03-13
KR20180108892A (ko) 2018-10-04
AU2012331244B2 (en) 2017-06-15
EP3075395A1 (en) 2016-10-05
JP5995984B2 (ja) 2016-09-21
UA111098C2 (uk) 2016-03-25
SG11201400924TA (en) 2014-09-26
AU2012331244A1 (en) 2014-04-17
MA35618B1 (fr) 2014-11-01
CA2854134C (en) 2020-04-21

Similar Documents

Publication Publication Date Title
AR113830A2 (es) Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
NZ717192A (en) Anti-inflammatory tripeptides
SMT201600416B (it) Uso di sali di 3-carbossi-n-etil-n,n-dimetilpropan-1-amminio nel trattamento di malattie cardiovascolari
BR112013027390A2 (pt) formulação farmacêutica
DOP2015000290A (es) Benzoxazoles sustituidos
UY34081A (es) Composición farmacéutica que comprende drotaverina
UA62955U (ru) Применение экстракта коры осины в качестве средства адаптогенного действия
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU20130146A7 (es) Sales de 3- carboxi-n-etil-n,n-dimetilpropan-1-aminio,método de reparación de las mismas y uso en el tratamiento de enfermedad cardiovascular

Legal Events

Date Code Title Description
FC Refusal